Natural human interferon β plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load

Internal Medicine

Volumn 47, Issue 21, 2008, Pages 1827-1834

  Katamura, Yoshio ^a   Suzuki, Fumitaka ^a   Akuta, Norio ^a   Sezaki, Hitomi ^a   Yatsuji, Hiromi ^a   Nomura, Norihiro ^a   Kawamura, Yusuke ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Suzuki, Yoshiyuki ^a   Saito, Satoshi ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Depression; Hepatitis C virus; Interferon ; Ribavirin

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BETA INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ANEMIA; ANXIETY DISORDER; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPANESE; MALE; MENTAL DISEASE; NEUTROPENIA; POLYMERASE CHAIN REACTION; RASH; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-BETA; MALE; MENTAL DISORDERS; MIDDLE AGED; PILOT PROJECTS; RETROSPECTIVE STUDIES; RIBAVIRIN; VIRAL LOAD;

EID: 56349132654     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.1436     Document Type: Article

References (25)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002.
2. Munns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358: 958-965, 2001.
3. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose: Ann Intern Med 140: 346-355, 2004.
4. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 345: 41-52, 2001.
5. Platanias LC, Uddin S, Colamonici OR. Tyrosine phosphorylation of the alpha and beta subunits of the type I interferon receptor. Interferon-beta selectively induces tyrosine phosphorylation of an alpha subunit-associated protein. J Biol Chem 269: 17761-17764, 1994.
6. Pellegrini S. John J. Shearer M. Kerr IM, Stark GR. Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway. Mol Cell Biol 9: 4605-4611, 1989.
7. Colamonici OR. Pfeffer LM. Structure of the human interferon alpha receptor. Pharmacol Ther 52: 227-233, 1991.
8. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 95: 15623-15628, 1998.
9. Alam JJ. Interferon-beta treatment of human disease. Curr Opin Biotechnol 6: 688-691, 1995.
10. Festi D, Sandri L, Mazzella G, et al. Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol 10: 12-16, 2004.
11. Kainuma M, Ogata N, Kogure T, et al. The efficacy of a herbal medicine (Mao-to) in combination with intravenous natural interferon-beta for patients with chronic hepatitis C, genotype 1b and high viral load: a pilot study. Phytomedicine 9: 365-372, 2002.
12. Kurosaki M, Enomoto N, Murakami T, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 25: 750-753, 1997.
13. Pellicano R, Craxi A, Almasio PL, et al. Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol 11: 4484-4489, 2005.
14. Chan HL, Ren H, Chow WC, Wee T. Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. Hepatology 46: 315-323, 2007.
15. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 105: 507-512, 1993.
16. Enomoto M, Tamori A, Kawada N, et al. Interferon-beta plus ribavirin for patients with hepatitis C virus genotype 1: a randomized pilot trial. Gut 55: 139-140, 2006.
17. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282: 103-107, 1998.
18. Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 35: 930-936, 2002.
19. Herrmann E, Lee JH, Marinos G, et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37: 1351-1358, 2003.
20. Frosi A, Sgorbati C, Bosisio Besteti M, Lodeville D, Vezzoli S, Vezzoli F. Interferon-α and -β in chronic hepatitis C: efficacy and tolerability. Clin Drug Invest 9: 226-231, 1995.
21. Bernardinello E, Cavalletto L, Chemello L, et al. Long-term clinical outcome after β-interferon therapy in cirrhotic patients with chronic hepatitis C. Hepatogastroenterology 46: 3216-3222, 1999.
22. Pellicano R, Palmas F, Cariti G, et al. Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 14: 1377-1382, 2002.
23. Habersetzer F, Boyer N, Marcellin P, et al. A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C. Liver 20: 437-441, 2000.
24. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 46: 991-998, 2007.
25. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 36: S237-S244, 2002.